store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Deferoxamine Mesylate (DFOM) 是一种铁螯合剂和铁死亡抑制剂。Deferoxamine Mesylate 可将游离铁结合成稳定的复合物,减少铁的积累。Deferoxamine Mesylate 可以上调 HIF-1α 水平,诱导细胞凋亡。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 99 | 现货 | ||
10 mg | ¥ 129 | 现货 | ||
25 mg | ¥ 193 | 现货 | ||
50 mg | ¥ 265 | 现货 | ||
100 mg | ¥ 373 | 现货 | ||
500 mg | ¥ 787 | 现货 | ||
1 g | ¥ 1,150 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 383 | 现货 |
产品描述 | Deferoxamine Mesylate (DFOM) is an iron chelator and iron death inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis. |
体外活性 |
方法:人宫颈癌细胞 HeLa 用 Deferoxamine Mesylate (3-100 μM) 处理 72 h,使用 Incucyte HD imaging system 检测细胞数目。 结果:Deferoxamine Mesylate 以浓度依赖的方式抑制细胞生长,在100 μM 下观察到显著的生长抑制。[1] 方法:人结直肠癌细胞 HT29 和 HCT116 用 Deferoxamine Mesylate (50-200 μM) 处理 48 h,使用 Western Blot 方法检测靶点蛋白表达水平。 结果:Deferoxamine Mesylate 以剂量依赖性方式诱导 HIF-1α 的显著表达。[2] 方法:人乳腺癌细胞 MDA-MB-231 和 MCF-7 用 Deferoxamine Mesylate (200 μM) 处理 24 h,使用 Flow Cytometry 方法检测细胞凋亡情况。 结果:Deferoxamine Mesylate 处理后,与未处理的细胞相比,MDA-MB-231 细胞的凋亡率没有变化,而 MCF-7 细胞的凋亡显著增加。[3] |
体内活性 |
方法:为研究 Deferoxamine Mesylate 是否能减轻实验小鼠的炎症和动脉粥样硬化,将 Deferoxamine Mesylate (100 mg/kg) 腹腔注射给载脂蛋白 E 缺陷 (apoE-/-) 小鼠,每天一次,持续十周。 结果:Deferoxamine Mesylate 使主动脉动脉粥样硬化病变的发展减少 26%。Deferoxamine Mesylate 还降低了血清 MCP-1 水平以及主动脉和心脏中促炎和巨噬细胞标志物的基因表达,同时增加了心脏和肝脏中转铁蛋白受体的蛋白质表达。相反,Deferoxamine Mesylate 治疗对血清胆固醇和甘油三酯水平没有影响。[4] 方法:为研究 Deferoxamine Mesylate 对 ob/ob 小鼠附睾脂肪组织中脂肪细胞功能障碍的影响,将 Deferoxamine Mesylate (100 mg/kg) 腹腔注射给 ob/ob 小鼠,每天一次,持续十五天。 结果:Deferoxamine Mesylate 通过减少活性氧和炎症标志物的分泌,通过增加抗氧化酶、HIF-1α 和 HIF-1α 靶向蛋白的水平,以及通过改变脂肪细胞铁、葡萄糖和脂质相关代谢蛋白,显著改善了脂肪组织生物学的重要参数。同时,Deferoxamine Mesylate 治疗后,肥大的脂肪细胞体积缩小,胰岛素信号通路相关蛋白也被激活。[5] |
细胞实验 | After cells were seeded onto the collagen-GAG discs and allowed to adhere for 3?hours, they were placed into a hypoxic incubator with 1% O2 or incubated under standard cell culture conditions with deferoxamine mesylate (DFO) added to final concentrations of 30, 60, or 120?μM. Scaffolds seeded with AdMSCs cultured under standard conditions were used as a control [3]. |
动物实验 | The animals were divided into 4 groups: sham, SAH, SAH+vehicle and SAH+DFX (100mg/kg) group. DFX was administered intraperitoneally 2 and 6 hours after hemorrhage followed by every 12 hours for a maximum of 7 days. The same time course and dosage of saline were administered in the SAH+vehicle group. Afterward, rats underwent behavioral testing and were euthanized at day 1, 3, 7 and 28 for brain water content calculation, immunohistochemistry or western blot assays. The study was performed in three parts. Part 1 measured the brain water content, Evan's blue extravasation, and ultrastructural abnormalities at day 1, 3 and 7 after SAH to evaluate the time-dependent changes in brain edema and BBB disruption (n = 4 per time point and group). Part 2 investigated the role of iron in SAH-induced BBB disruption at day 1, 3 and 7 by brain water content (n = 4, per time point and group), Evan's blue extravasation (n = 4, per time point and group), transmission electron microscopy (n = 4, per time point and group), immunohistochemistry (n = 4, per time point and group) and western blot analysis (n = 3, per time point and group). Part 3 compared the acute (n = 61, per group at day 1; n = 42, per group at day 3; n = 23, per group at day 7) and long term (n = 4, per group at day 28) neurological function after SAH in each group to determine the effect of iron chelation on SAH-induced neurologic impairment [4]. |
别名 | desferrioxamine B, Desferrioxamine B mesylate, DFO, DFOM, 去铁铵, 甲磺酸去铁胺 |
化合物与蛋白结合的复合物 |
Crystal structure of ferric R-state human methemoglobin bound to maleimide-deferoxamine bifunctional chelator (DFO) |
分子量 | 656.79 |
分子式 | C26H52N6O11S |
CAS No. | 138-14-7 |
store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 152.3 mM
H2O: 20.83 mg/mL (31.72 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 1.5226 mL | 7.6128 mL | 15.2256 mL | 38.0639 mL |
5 mM | 0.3045 mL | 1.5226 mL | 3.0451 mL | 7.6128 mL | |
10 mM | 0.1523 mL | 0.7613 mL | 1.5226 mL | 3.8064 mL | |
20 mM | 0.0761 mL | 0.3806 mL | 0.7613 mL | 1.9032 mL | |
DMSO | 50 mM | 0.0305 mL | 0.1523 mL | 0.3045 mL | 0.7613 mL |
100 mM | 0.0152 mL | 0.0761 mL | 0.1523 mL | 0.3806 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Deferoxamine Mesylate 138-14-7 Apoptosis Autophagy Chromatin/Epigenetic Metabolism Neuroscience Others Mitophagy Beta Amyloid Ferroptosis HIF/HIF Prolyl-Hydroxylase HIFs neovascularization TAMSCs desferrioxamine B diabetes mellitus Akt PKB Protein kinase B SH-SY5Y Hypoxia-inducible factors Deferoxamine Desferrioxamine B mesylate DFO Desferrioxamine B Mesylate Inhibitor MEFs cancer Alzheimer’s disease HIF-PH Reactive Oxygen Species BMMSCs inhibit DFOM 去铁铵 COVID-19 甲磺酸去铁胺 inhibitor